Targeted Tuberculin Testing And Treatment Of Latent Tuberculosis Infection Pdf
File Name: targeted tuberculin testing and treatment of latent tuberculosis infection .zip
- Targeted Tuberculin Testing and Interpreting Tuberculin Skin Test Results
- TB Diagnostic Reference Documents
- Treatment of Latent Tuberculosis Infection
Targeted Tuberculin Testing and Interpreting Tuberculin Skin Test Results
The journal publishes 6 issues per year, mainly about respiratory system diseases in adults and clinical research. This work can range from peer-reviewed original articles to review articles, editorials, and opinion articles. The journal is printed in English, and is freely available in its web page as well as in Medline and other databases. The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years. CiteScore measures average citations received per document published. Read more. SRJ is a prestige metric based on the idea that not all citations are the same.
FERN R. Related Editorial. Patient information: See related handout on tuberculosis , written by the authors of this article. Latent tuberculosis infection LTBI is a condition in which a person is infected with Mycobacterium tuberculosis , but does not currently have active tuberculosis disease. Because 5 to 10 percent of persons with LTBI are at risk of progressing to active disease, identification and treatment of LTBI are essential for the elimination of tuberculosis. Screening is recommended for high-risk persons, including immigrants; residents and employees of congregate living facilities; and persons infected with human immunodeficiency virus.
Latent tuberculosis infection LTBI is the persistence of an immunological response to Mycobacterium tuberculosis antigen stimulation without any clinically active disease. To control the active infection, the shrinking of the magnitude of the pool of latent infection is required. There has been a lot of emphasis in the past few decades on the elimination of TB. While treatment of active disease is by far the major intervention in this regard, LTB treatment forms an important yet undervalued facet. The diagnosis and treatment of LTBI are hindered by the cost implications of testing, lack of a consensus on the tests recommended, and side effects of treatment. Treatment of LTBI in low prevalence high to upper-middle-income countries is feasible, as elimination of this reservoir of infection will reduce the burden of the disease. However, the scenario in high prevalence countries such as India is quite the opposite.
TB Diagnostic Reference Documents
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq cdc. Type Accommodation and the title of the report in the subject line of e-mail. David L. Cohn, M. O'Brien, M. Lawrence J.
Treatment of Latent Tuberculosis Infection
Pulmonary tuberculosis is a common disease in Saudi Arabia. As most cases of tuberculosis are due to reactivation of latent infection, identification of individuals with latent tuberculosis infection LTBI who are at increased risk of progression to active disease, is a key element of tuberculosis control programs. Whereas general screening of individuals for LTBI is not cost-effective, targeted testing of individuals at high risk of disease progression is the right approach. Treatment of those patients with LTBI can diminish the risk of progression to active tuberculosis disease in the majority of treated patients. This statement is the first Saudi guideline for testing and treatment of LTBI and is a result of the cooperative efforts of four local Saudi scientific societies.
David L. New recommendations for targeted tuberculin testing and treatment of latent tuberculosis TB infection have recently been published. Changes in nomenclature from screening to targeted tuberculin testing and from preventive therapy to treatment of latent TB infection LTBI are intended to promote more widespread implementation by programs and health care providers.
Madhukar Pai and Philip Hopewell. Produced by the WHO. Surveillance of tuberculosis in Europe . Produced by EuroTB. Produced by the American Thoracic Society.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details. An effective strategy for reducing the transmission, morbidity, and mortality of active disease is the identification and treatment of latent tuberculosis infection LTBI to prevent progression to active disease.
David L. New recommendations for targeted tuberculin testing and treatment of latent tuberculosis TB infection have recently been published. Changes in nomenclature from screening to targeted tuberculin testing and from preventive therapy to treatment of latent TB infection LTBI are intended to promote more widespread implementation by programs and health care providers. Targeted tuberculin testing is designed to identify persons at high risk for TB and is discouraged for persons at low risk.
The treatment of latent tuberculosis infection LTBI is an essential component of tuberculosis TB elimination in regions that have a low incidence of TB. However, the decision to treat individuals with LTBI must consider the limitations of current diagnostic tests for LTBI, the risk of developing active TB disease, the potential adverse effects from chemoprophylactic therapy, and the importance of treatment adherence. When an individual has been diagnosed with LTBI and active TB has been ruled out, this is followed by an evaluation of the risks and benefits of LTBI treatment within the context of the regional epidemiology of TB and public health priorities. As the duration of treatment of LTBI therapy is many months, therapy must be offered within a plan that monitors for adverse drug reactions and emphasizes adherence. For latent multidrug-resistant TB MDR-TB or extensively drug-resistant TB XDR-TB infection, the management is more complicated as there are few options for chemoprophylactic therapy and little evidence regarding the efficacy or risks of these regimens.